PuraPharm Corporation Limited Overview
PuraPharm is a founder-controlled Hong Kong Chinese-medicine company. It built its franchise on concentrated Chinese medicine granules (CCMG), sold under the Nong's® (農本方) brand. CCMG are modern, instantly soluble extracts that replace the traditional practice of boiling raw herbs. The group is vertically integrated. It runs herb plantations in Guizhou, a GMP/TGA/PIC/S-certified extraction plant in Nanning, a CNAS ISO 17025 laboratory, and distribution to Hong Kong hospitals, NGOs and private practitioners. It also operates 22 Nong's clinics in Hong Kong and a small Shenzhen network. It claims more than 80% share of Hong Kong's CCMG market, and that market now generates most of its profit. Its former growth engine, Mainland China CCMG, has effectively collapsed to zero external sales since national standards took effect in November 2021. Revenue has roughly halved since FY2021. The group has lost money for five consecutive years and carries HK$314M of debt against HK$12M of cash. It is a niche quality leader operating under a going-concern cloud.
Company's own description (paraphrased from AR2025 Corporate Profile)
The company describes itself as a leading Hong Kong-based Chinese medicine group. Its main activities are the research, development, production, marketing and sale of CCMG products under the Nong's® brand. It states that it is one of only five licensed CCMG manufacturers in China and the only non-PRC company licensed by the CFDA (now NMPA) to make and sell CCMG there. Its in-house CNAS ISO 17025 laboratory issues safety reports recognised in more than 70 countries. It has supplied CCMG to most Hong Kong hospitals and healthcare institutions with TCM clinics since 2004. It describes itself as the largest CCMG supplier in Hong Kong and a leading Chinese medicine clinic chain there. It also markets over-the-counter health brands: PuraGold®, Oncozac®, Immuzac® and Haveron®.
The filings describe the group's principal activities as:
-
R&D, production and sale of CCMG and Chinese healthcare products
-
plantation and trading of raw Chinese herbs
-
manufacture and sale of TCM decoction pieces (中藥飲片)
-
Chinese medical diagnostic services
(FY25 Ann. note 1; IR26 note 1)
Independent characterisation
| Revenue type | HKD K | % of total |
|---|---|---|
| Sale of CCMG products and raw Chinese herbs | 230,673 | 68.6 |
| Sale of Chinese healthcare products | 92,557 | 27.5 |
| Rendering of diagnostic services | 12,883 | 3.8 |
| Total | 336,113 | 100.0 |
In economic terms PuraPharm today is a Hong Kong CCMG distributor and manufacturer with a captive Mainland factory, plus three adjacent and much less profitable businesses: consumer health supplements, clinics, and upstream herbs. The key analytical point is that the "China CCMG and plantation" segment generated only HK$1k of external revenue in FY2025. Yet it booked HK$176.0M of inter-segment sales and a segment profit of HK$20.2M (FY25 Ann. note 3). The Nanning/Guizhou asset base now functions mainly as the manufacturing and supply hub for Hong Kong sales. That base accounts for the bulk of PP&E (HK$265.5M) and of RMB-denominated debt (HK$267.2M of HK$323.8M borrowings).
Business model and revenue mix (FY2025, FY25 Ann. note 4):
Product vs service: 96.2% of revenue is product sales recognised at a point in time. 3.8% is diagnostic services recognised over time. There is no subscription or licensing revenue. The clinic management system, CMCMS/TCMA 3.0, supports the clinics and is not reported as a separate revenue line.
Value chain position: fully integrated, from cultivation (Guizhou) through extraction and granulation (Nanning, plus pilot plants in Osaka and California), testing (CNAS lab), B2B distribution (HK hospitals, NGOs, private practitioners) and B2C retail (Nong's clinics, pharmacies, cross-border e-commerce).
Customer types: Hong Kong public hospitals and NGO-run TCM clinics, private Chinese medicine practitioners, retail consumers (clinic patients, drugstore and convenience-store buyers, online buyers in Mainland China), and US/European distributors and practitioners (KAN Herb). Mainland hospitals were historically a key channel but are being deliberately de-emphasised.
End-markets: Hong Kong prescription TCM; Mainland China TCM (now via private clinics and cross-border e-commerce); US/European herbal practitioner markets; Japanese health-food market.
Strategy
Stated strategy (AR2025 Chairman's Statement; reiterated in IR26, paraphrased)
-
Shift from public hospital channels to private healthcare. Reduce reliance on Mainland public-hospital procurement; expand into private hospitals, clinics and direct-to-consumer.
-
Expand Nong's® clinics in the Greater Bay Area. Grow the Shenzhen network and explore a franchise model under strict capital discipline. Note that the network contracted from 4 to 2 clinics in H1 2026.
-
Accelerate cross-border e-commerce for healthcare products. Increase digital marketing to capture Mainland demand for premium Hong Kong-branded products.
-
Strengthen international expansion. Use the US and Japanese plants to develop products for Canada, the USA, Japan, Southeast Asia, Australia and Korea (AR2025 Prospects).
The mission statement is about extending healthy, happy lives through the modernisation of Chinese medicine. The stated aim is to become the most admired herbal medicine company (AR2025).
Strategic initiatives in the last 24 months
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Capital reduction | Q1 2025 | Par value cut from US$0.1 to US$0.001; HK$303.8M offset against accumulated losses, enabling future dividend capacity and share issuance below old par | Completed |
| Patent Licence Agreement (connected) | Signed 25 Jul 2025; completed 30 Oct 2025 | 93.5M shares at HK$0.43 (HK$40.2M) for patent rights; supports a clinical-trial pipeline across HK, Canada and the US | Completed; trials unfunded beyond HK$19.8M |
| Providence Discovery Fund subscription | Signed 25 Jul 2025; completed 30 Oct 2025 | 46.5M shares at HK$0.43, raising HK$20.0M gross / HK$19.8M net; Dong Zimeng joins the board | Completed; proceeds unutilised at end-2025 |
| Convertible bond | Signed 26 Feb 2026; completed 23 Mar 2026 | HK$20M, 6% coupon, 2-year (extendable to 3), conversion at HK$0.49. Proceeds: HK$10M working capital, HK$5M debt repayment, HK$4.85M production upgrade and CCMG R&D. | HK$15M used by 30 Jun 2026 |
| GBA clinic expansion and franchise | 2023–2026 | 1 Shenzhen clinic (2023), 3 (2024), 4 (2025), 2 (Jun 2026) | Contracting |
| Cross-border e-commerce push | 2025–2026 | Higher A&P spend; H1 2026 S&D +33.4% | Sales −20.4% in H1 2026 |
| Cost programme | 2023–2026 | Headcount 662 to 441; S&D −76% since FY2021; H1 2026 admin −20.8% | Ongoing; no formal savings target disclosed |
| Debt reduction and refinancing | Ongoing | Borrowings HK$385M (FY23) to HK$314M (Jun 2026); loan-term deferrals negotiated | Ongoing |
| ESG climate targets | 2030 vs 2020 baseline | Reductions in GHG, energy, water and waste intensity. Percentage targets not captured in the reviewed extract. Solar panels planned. | Intensity rose in FY2025 |
Medium-term targets and guidance
Management provides no quantitative financial guidance or medium-term targets. The outlook language describes "measured optimism" for H2 2026 (IR26). Going-concern plans refer to restructuring the product mix, cost control, drawing and renewing bank facilities, finding new financing, and seeking investors (IR26 note 2).
Products & Services
Pricing models are not publicly disclosed for any product line.
Hong Kong / China CCMG (Nong's® professional range)
| Product / line | Description and specifications | Target customer | Launch / latest | Source |
|---|---|---|---|---|
| Nong's® CCMG single-herb granules | Herbs extracted via dynamic fluid extraction, low-temperature concentration and spray/freeze/vacuum/fluid-bed drying. Designed to match decoction efficacy, taste and aroma and to dissolve instantly. Tested for heavy metals, pesticides and microbes using DNA fingerprinting, FTIR and UHPLC. | Hospitals, NGO clinics, private practitioners | Since 2004 in HK hospitals | AR2025 |
| Nong's® CCMG combination formulae | Classical multi-herb formulae; part of the >600 professional SKUs. The group cites its 2002 NATCM combo-formula research mandate. | Same | Ongoing | AR2025 |
| Radix Astragali Formula Granules | Verified under the USP Dietary Ingredient Verification Program. | Practitioners, export | USP-verified 2014 | AR2025 |
| Qing Fei Pai Du Tang granules | COVID-19 formula recommended nationally by NATCM; emergency approval for the Nanning plant. | PRC hospitals | Feb 2020 | AR2025 |
| Kang Fu Yi Hao Fang granules | COVID-19 recovery formula; emergency approval. | PRC hospitals | Feb 2020 | AR2025 |
| TCM decoction pieces (中藥飲片) and raw herbs | Guizhou plantation, which claims supply of 500+ herb varieties; mainly internal supply. | Group factories, traders | Since 2017 acquisition | AR2025 ESG; FY25 Ann. |
Chinese Healthcare Products (OTC / consumer)
| Brand / product | Description | Target | Launch / latest | Source |
|---|---|---|---|---|
| Oncozac® (安固生®) | Sole active ingredient ONCO-Z® Coriolus versicolor (Yunzhi) extract. Claimed as the first TCM ingredient verified by the USP Dietary Ingredient Verification Program. Supported by the "Living with Cancer" TV commercial (2023 Cannes finalist). | Cancer patients and carers; consumers | USP-verified 2009; campaign 2023 | AR2025 |
| PuraGold® (金靈芝®) | Lingzhi (reishi) health product line; trademark registered. Detailed specifications not disclosed. | Consumers (HK and overseas) | — | AR2025 |
| Immuzac® (益抗適®) | Immune-support product developed with proprietary research technology. | Consumers | — | AR2025 |
| Immuzac+™ | Immuzac® fortified with vitamin C; manufactured in Japan (SODX). | Consumers | 2,020 | AR2025 |
| Haveron® (烏髮濃®) | Hair-health OTC product; specifications not disclosed. | Consumers | — | AR2025 |
| Nong's® OTC Formula range | Classical formulae in consumer packaging; repackaged in 2019. | Consumers via pharmacies | Repackaged 2019 | AR2025 |
| Nong's® OTC Chinese Medicine Capsules | Range of ten capsule products for general relief and wellbeing. | Consumers | 2,019 | AR2025 |
| Nong's® "indigenous herbs" health foods | "Homology of medicine and food" products applying TCM "four natures / five flavours" theory. | Consumers | 2,021 | AR2025 |
| Nong's® Instant Herbal Drinks | Self-Heal Plant, Monk Fruit and Wolfberry; sold in drugstore and convenience chains; TV commercial support. | Younger consumers | Sep 2023 | AR2025 |
| KAN® herbal formulas | More than 300 herbal formula products, manufactured at Kan Herb Company's GMP facility in California. | US/European distributors and practitioners | Acquired Mar 2017 | AR2025 |
| SODX health foods | Antioxidants, fermented health foods and propolis products in granule, tablet and capsule forms; Health Food GMP pilot factory in Osaka. | Japanese market; OEM | Acquired Aug 2017 | AR2025 |
Clinics and services
| Offering | Description | Source |
|---|---|---|
| Nong's® Chinese medicine clinics | 22 clinics in Hong Kong, mostly in shopping malls. 2 in Shenzhen at 30 Jun 2026, down from 4 at end-2025. Staffed by registered, university-trained CMPs who prescribe Nong's CCMG. Services include consultation, acupuncture and cupping. | AR2025; IR26 |
| Central flagship acupuncture centre | Hong Kong's largest clinic-grade acupuncture centre (per the company), targeting higher-spending customers. | FY22 Ann.; AR2025 |
| Integrated mammary gland centre | First private integrated Chinese–Western centre for mammary disease in HK (50th clinic). Current status not disclosed. | AR2025 |
| CMCMS / TCMA 3.0 | Patented, automated clinic and hospital management and dispensing system. Version 3.0 (cloud-based, real-time sync, consultation analytics) rolled out July 2021. | AR2025 |
| Testing services | CNAS ISO 17025 laboratory issuing safety reports recognised in 70+ countries. Mainly internal; external revenue not disclosed. | AR2025 |
Pipeline / development assets
| Asset | Status | Source |
|---|---|---|
| Ren Shu Chang Le Granules (仁朮腸樂顆粒), IBS | Phase 2 clinical trial entered in 2018. HK$6.4M of IPO proceeds remains unutilised, of which HK$4.3M is earmarked for it; expected use by December 2026. | AR2025; FY25 Ann. |
| Patents licensed in Oct 2025 (Patent Licence Agreement; licensor identified in IR26 as BAGI Research Limited) | Valued at HK$40.2M and paid in shares. Providence subscription proceeds (HK$19.8M) are earmarked for HK Phase 1–3 trials and NDA, Canadian Class 3 Natural Health Product registration, and US toxicology/IND. The therapeutic subject of the patents is not identified in the materials reviewed. | FY25 Ann.; IR26 note 15 |
| Two new proprietary Chinese medicines (IPO use of proceeds) | Delayed; R&D taking longer than expected. | FY25 Ann. |
Financial Narrative
All figures are HK$ million unless stated. Sources: FY22, FY24 and FY25 Announcements (audited) and SA for derived operating income. EBITDA is analyst-computed as pre-tax loss + finance costs + depreciation of PP&E + depreciation of right-of-use assets + amortisation of intangibles. It includes impairments and fair-value losses.
Margins (%, analyst-computed)
Revenue CAGR FY2021–FY2025 (4 years): −15.5% (analyst-computed). FY2018 peak revenue of HK$745.5M to FY2025 is a 7-year CAGR of about −10.7%.
Major non-cash items (HK$ M):
-
FY2021: goodwill impairment 67.3; biological-asset fair-value loss 47.5; receivable impairment 17.0
-
FY2022: biological-asset loss 36.7; receivable impairment 10.5
-
FY2023: biological-asset loss 16.8; PP&E impairment 12.8; goodwill impairment 3.0
-
FY2024: PP&E/ROU impairment 2.4
-
FY2025: reversal of receivable impairment +8.2; ROU impairment 1.3
Balance sheet
30 June 2026 (IR26):
-
Total assets: 699.8
-
Cash: 12.2
-
Borrowings: 314.4 (current 272.8, non-current 41.6)
-
Convertible bonds: 19.5
-
Leases: 36.7
-
Equity: 125.0
-
Net current liabilities: 256.8
The FY2025 jump in intangibles to HK$67.0M reflects the patent rights acquired for HK$40.2M in shares (IR26 note 15).
Cash flow
Sources: filed cash-flow statements. FY2025 capex and intangible additions are from SA/S&P because the FY25 Ann. extract does not itemise investing flows; H1 2025 showed nil PP&E purchases. H1 2026 operating cash flow was −HK$1.3M, versus +HK$31.9M in H1 2025 (IR26).
Ratios (analyst-computed)
The company's own gearing ratio (borrowings ÷ equity) was 1.2 (FY2021), 1.8, 2.5, 3.1 and 2.5 (FY2025), and 2.5 at 30 Jun 2026 (company filings).
Commentary on trends, inflections and drivers
Revenue. The defining inflection is November 2021. Mainland national CCMG standards came into force at a time when only a limited number of standards existed: 342 by end-2024 and 396 by end-2025, against roughly 500 varieties typically needed by hospitals (FY24/FY25 Ann.). Hospitals stocked up ahead of the change and prices reset higher. PuraPharm's Mainland CCMG revenue went from HK$353.0M (FY2021) to HK$117.8M, HK$50.8M, HK$24.8M and effectively zero in FY2025, as management actively "downplayed" hospital channels. Hong Kong held up well through FY2024, helped by pricing gains and NGO and private-practitioner wins. In FY2025 it fell 7.4% on weaker local consumption and competition, then grew 2.0% in H1 2026.
Gross margin. Margin compressed from 64.2% to the low-50s as the high-margin Mainland business disappeared and standards-compliant production raised costs. It has been stable at about 53–54% for three years and reached 57.8% in H1 2026, helped by production-cost control (IR26).
Operating costs. Management has cut selling and distribution expenses by 76% since FY2021 (HK$220.0M to HK$52.5M) and reduced headcount by 35% (675 to 441). Administrative costs have proved stickier at about HK$152–172M, partly because R&D, clinic rents and Nanning's fixed overhead sit there. H1 2026 administrative expenses fell 20.8% to HK$68.3M, the most significant cost step in two years. Advertising rose 33% to support healthcare products, but healthcare product sales still fell 23.4%.
Below the line. Finance costs remain about 6% of revenue (HK$20.7M in FY2025) and absorb most of the segment profit. The FY2021–FY2023 losses were heavily driven by non-cash write-downs on the Guizhou plantation (biological assets, PP&E, goodwill), which totalled more than HK$200M across the three years. These are now exhausted. The residual loss of about HK$35M per year in FY2024–FY2025 is structural: segment profit of about HK$60–70M does not cover corporate overhead (about HK$74M) plus non-lease interest (about HK$20M).
Cash flow and balance sheet. Working-capital release funded about HK$200M of debt reduction between FY2021 and FY2025. Receivables fell from HK$261M to HK$56M and inventories from HK$166M to HK$99M; total borrowings fell from HK$499.7M to HK$323.8M. This tailwind is largely spent. FY2025 operating cash flow fell to HK$28.5M as payables were paid down (bills payable eliminated), and H1 2026 operating cash flow turned negative. Equity was replenished in FY2025 by HK$60.2M of share issuance (HK$40.2M of it non-cash, for patents). The current ratio of 0.47 and the reliance on rolling RMB bank lines are the central financial risk.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment (Latest Name) Overview
| Segment (latest name) | Contents | Key products/services |
|---|---|---|
Hong Kong (and overseas) CCMG | CCMG sales in HK, excluding sales through own clinics | Nong's® single and combination granules (>600 SKUs) sold to hospitals, NGOs and private practitioners |
Chinese Healthcare Products | Production and sale of health products in HK, Mainland, USA and Japan | PuraGold®, Oncozac®, Immuzac®/Immuzac+™, Haveron®, Nong's OTC capsules and instant drinks, KAN formulas (US/EU), SODX health foods (Japan) |
Clinics | Diagnostic services and CCMG dispensing in own clinics | 22 HK Nong's clinics; 2 Shenzhen clinics (Jun 2026) |
China CCMG and Plantation | Mainland CCMG production and sale; herb plantation and trading; decoction pieces | Nanning plant, Guizhou plantation; now mostly inter-segment supply |
Revenue by Segment
| Segment (HKD Mn, external revenue) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Hong Kong CCMG | 162.7 | 192.1 | 208.4 | 207.6 | 192.3 |
Chinese Healthcare Products | 78.1 | 78.9 | 82.0 | 84.3 | 92.6 |
Clinics | 50.0 | 46.1 | 53.7 | 56.3 | 51.2 |
China CCMG | 353.0 | 117.8 | 50.8 | 24.8 | — |
Plantation | 15.7 | 13.3 | 11.9 | 9.1 | — |
China CCMG and Plantation combined | 368.7 | 131.0 | 62.7 | 33.9 | 0.0 |
Total Group | 659.6 | 448.1 | 406.9 | 382.1 | 336.1 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment by Segment Result
| Segment result (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Hong Kong CCMG | 41.1 | 54.0 | 74.7 | 68.7 | 47.2 |
Chinese Healthcare Products | 9.3 | -2.0 | -16.4 | 9.6 | 1.7 |
Clinics | -8.0 | -5.7 | 1.2 | 0.1 | -9.6 |
China CCMG | 61.9 | -23.2 | -12.4 | -0.1 | — |
Plantation | -141.9 | -54.1 | -47.4 | -8.3 | — |
China CCMG and Plantation combined | -79.9 | -77.4 | -59.8 | -8.4 | 20.2 |
Total segment result | -37.6 | -31.1 | -0.3 | 70.0 | 59.5 |
Segment margin (%)
| Segment margin (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Hong Kong CCMG | 25.3 | 28.1 | 35.8 | 33.1 | 24.5 |
Chinese Healthcare Products | 11.9 | -2.5 | -20.0 | 11.4 | 1.8 |
Clinics | -16.0 | -12.4 | 2.2 | 0.2 | -18.8 |
Segment Revenue
| Segment | FY2025 HKD K | % of total | FY2024 HKD K | % of total | YoY % |
|---|---|---|---|---|---|
HK CCMG | 192,317 | 57.2 | 207,591 | 54.3 | -7.4 |
Healthcare products | 92,557 | 27.5 | 84,302 | 22.1 | +9.8 |
Clinics | 51,238 | 15.2 | 56,313 | 14.7 | -9.0 |
China CCMG and plantation | 1 | 0.0 | 33,884 | 8.9 | -100.0 |
Total | 336,113 | 100 | 382,090 | 100 | -12.0 |
Segment Revenue (Half-Yearly)
| Segment | H1 2026 rev. HKD K | H1 2025 rev. HKD K | YoY % | H1 2026 result | H1 2025 result |
|---|---|---|---|---|---|
HK and overseas CCMG | 93,914 | 92,103 | +2.0 | 16,655 | 42,802 |
Healthcare products | 40,368 | 52,699 | -23.4 | 5,980 | 11,989 |
Clinics | 24,541 | 25,765 | -4.8 | -4,967 | -2,578 |
China CCMG and plantation | 850 | 1,728 | -50.8 | 10,006 | -12,929 |
Total | 159,673 | 172,295 | -7.3 | 27,674 | 39,284 |
Income Statement and Per-Share Data
| Metric (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue | 659.6 | 448.1 | 406.9 | 382.1 | 336.1 |
Cost of sales | 236.2 | 185.4 | 190.2 | 176.9 | 156.0 |
Gross profit | 423.4 | 262.7 | 216.6 | 205.1 | 180.2 |
Selling and distribution expenses | 220.0 | 157.4 | 91.7 | 64.9 | 52.5 |
Administrative expenses | 168.5 | 157.9 | 171.5 | 159.5 | 152.1 |
Operating income (SA definition) | 15.1 | -68.3 | -53.2 | -18.3 | -16.2 |
Finance costs | 27.0 | 24.2 | 27.4 | 23.7 | 20.7 |
D&A (PP&E + ROU + intangibles) | 50.1 | 48.7 | 48.6 | 54.6 | 44.5 |
EBITDA (analyst-computed, incl. impairments) | -40.0 | -46.3 | -26.3 | 49.2 | 30.8 |
Pre-tax income | -117.2 | -119.2 | -102.3 | -29.1 | -34.4 |
Income tax expense | 4.7 | 1.0 | 3.8 | 6.3 | 0.8 |
Net income attributable | -121.9 | -120.2 | -106.1 | -35.4 | -35.2 |
EPS basic and diluted (HK cents) | -30.95 | -30.47 | -26.85 | -8.97 | -8.41 |
Dividend per share (HKD) | 0 | 0 | 0 | 0 | 0 |
Margin (%)
| Margin (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin | 64.2 | 58.6 | 53.2 | 53.7 | 53.6 |
Operating margin (SA op. income) | 2.3 | -15.2 | -13.1 | -4.8 | -4.8 |
EBITDA margin | -6.1 | -10.3 | -6.5 | 12.9 | 9.2 |
Net margin | -18.5 | -26.8 | -26.1 | -9.3 | -10.5 |
S&D expense / revenue | 33.4 | 35.1 | 22.5 | 17.0 | 15.6 |
Balance Sheet
| Metric (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets | 1,205.9 | 1,016.5 | 844.0 | 715.7 | 693.8 |
Cash and cash equivalents | 59.7 | 75.8 | 20.1 | 12.8 | 16.2 |
Restricted cash and pledged deposits | 25.4 | 31.2 | 27.1 | 25.5 | 5.0 |
Bank and other borrowings — current | 407.7 | 410.1 | 304.0 | 250.5 | 268.3 |
Bank and other borrowings — non-current | 92.0 | 48.7 | 81.1 | 89.2 | 55.5 |
Total borrowings | 499.7 | 458.8 | 385.1 | 339.7 | 323.8 |
Lease liabilities | 32.3 | 44.3 | 39.7 | 24.0 | 27.3 |
Net debt (borrowings − cash) | 440.0 | 383.0 | 365.0 | 326.9 | 307.6 |
Total equity | 401.6 | 258.3 | 153.2 | 111.2 | 130.5 |
Goodwill | 21.0 | 21.0 | 17.9 | 17.9 | 17.9 |
Other intangible assets | 41.1 | 37.6 | 34.7 | 31.6 | 67.0 |
Inventories | 166.0 | 172.4 | 175.6 | 123.6 | 99.2 |
Trade and bills receivables | 261.4 | 131.9 | 80.9 | 57.5 | 56.4 |
Trade and bills payables | 140.7 | 137.9 | 146.4 | 132.2 | 85.2 |
Working capital (net current assets) | -54.5 | -179.4 | -221.5 | -222.6 | -252.3 |
Cash Flow
| Metric (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow | -14.5 | 88.5 | 79.6 | 104.0 | 28.5 |
Capex (purchase of PP&E) | 3.1 | 20.8 | 19.2 | 14.8 | 0.3 |
Additions to intangibles | 3.5 | 1.9 | 2.5 | 1.6 | 2.6 |
Free cash flow (OCF − PP&E capex) | -17.6 | 67.7 | 60.4 | 89.2 | 28.2 |
Lease principal paid | 33.7 | 19.0 | 21.9 | 18.8 | 18.4 |
FCF after leases | -51.3 | 48.6 | 38.5 | 70.4 | 9.8 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Cash equity issued | 0 | 0.8 | 0 | 0 | 20.0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%, avg equity; FY2021 on year-end equity) | -30.4 | -36.4 | -51.6 | -26.8 | -29.1 |
ROA (%, avg assets; FY2021 on year-end assets) | -10.1 | -10.8 | -11.4 | -4.5 | -5.0 |
Pre-tax ROIC (%, SA op. income ÷ equity + debt + leases − cash) | 1.7 | -10.0 | -9.5 | -3.9 | -3.5 |
Current ratio (x) | 0.92 | 0.73 | 0.61 | 0.55 | 0.47 |
Debt / equity (x, borrowings ÷ equity) | 1.24 | 1.78 | 2.51 | 3.05 | 2.48 |
Net debt / EBITDA (x; 0 = not meaningful, negative EBITDA) | 0 | 0 | 0 | 6.6 | 10.0 |
Interest coverage (x, SA op. income ÷ finance costs) | 0.56 | -2.82 | -1.94 | -0.77 | -0.78 |
Asset turnover (x) | 0.55 | 0.40 | 0.44 | 0.49 | 0.48 |
DSO (days) | 145 | 107 | 73 | 55 | 61 |
DIO (days) | 257 | 339 | 337 | 255 | 232 |
DPO (days) | 217 | 272 | 281 | 273 | 199 |
Cash conversion cycle (days) | 184 | 175 | 128 | 37 | 94 |
Revenue by Region
| Region (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Hong Kong | 242.5 | 281.5 | 305.3 | 305.5 | 291.8 |
Chinese Mainland | 374.1 | 132.3 | 62.9 | 35.3 | 2.6 |
Other countries/regions | 43.0 | 34.2 | 38.7 | 41.2 | 41.7 |
Total | 659.6 | 448.1 | 406.9 | 382.1 | 336.1 |
Region YoY growth (%)
| Region YoY growth (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Hong Kong | 16.1 | 8.4 | 0.1 | -4.5 |
Chinese Mainland | -64.6 | -52.5 | -43.8 | -92.6 |
Other countries/regions | -20.4 | 13.0 | 6.5 | 1.1 |
Revenue by Region (FY2021–FY2024)
| Healthcare products by market (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
United States | 31.5 | 26.8 | 30.1 | 30.9 |
Japan | 9.4 | 7.5 | 7.8 | 9.4 |
Hong Kong (and Mainland from FY2023) | 37.1 | 44.5 | 44.1 | 44.0 |
Total | 78.1 | 78.9 | 82.0 | 84.3 |
Share Price History
| Date | Price (HKD) | Source / context |
|---|---|---|
8 Jul 2015 | 5.98 | IPO price (etnet). Pre-2020 rights issue, so not directly comparable. |
28 Dec 2022 | 1.28 | Closing price immediately before the 29 Dec 2022 option grant (FY22 Ann.) |
Feb 2025 | ~0.52 | etnet quote, 4 Feb 2025 |
25 Jul 2025 | 0.455 | Close on placement signing date (FY25 Ann.) |
26 Feb 2026 | 0.335 | Close on convertible bond signing date (IR26) |
5 Jun 2026 | 0.30 | Google Finance; 52-week range HK$0.28–0.52 |
20 Aug 2026 | 0.28 | SA |
9 Oct 2026 | 0.242 | SA |
Valuation Multiples
| Multiple | PuraPharm | China TCM (0570.HK) |
|---|---|---|
Market cap | HK$129.7M | HK$7.96bn (roic.ai) |
Enterprise value | ≈HK$488M (equity + borrowings 314.4 + CB 19.5 + leases 36.7 − cash 12.2) | Not computed |
P/E | n.m. (TTM net loss ≈HK$27.7M) | n.m. (FY25 loss) |
EV/Sales (TTM revenue ≈HK$323.5M) | ≈1.5x | Not computed |
EV/EBITDA (TTM EBITDA ≈HK$39.4M, incl. items) | ≈12.4x | Not computed |
P/B (equity HK$125.0M) | ≈1.04x | Not computed |
P/TBV | ≈3.9x (tangible equity ≈HK$41.7M) | Not computed |
Dividend per share (HKD)
| Dividend per share (HKD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Ordinary DPS | 0 | 0 | 0 | 0 | 0 |
Bucket Details
| Bucket | HKD K |
|---|---|
Within 1 year or on demand | 272,834 |
Year 2 | 11,831 |
Years 3–5 | 29,758 |
Total bank and other borrowings | 314,423 |
Convertible bonds (HK$20M principal; matures Mar 2028, extendable to Mar 2029) | 19,488 carrying value |
Analyst Conclusions
Management guidance
No numerical guidance. Management expresses "measured optimism" for H2 2026. It cites GBA clinic expansion and healthcare-product growth as drivers, alongside continued cost control and refinancing (IR26).
Consensus
Not available; no coverage.
Bull case
-
The core is profitable and cheap at the enterprise level. The integrated HK CCMG plus Nanning chain generated HK$67.4M of combined segment profit in FY2025 (analyst-computed). On a ≈HK$488M EV, a normalised EBITDA of HK$40–50M implies about 10–12x, reasonable for a near-monopoly in a defensible niche if refinancing succeeds.
-
Cost and loss trajectory is improving. H1 2026 net loss fell 34.7% to HK$14.2M, gross margin rose to 57.8% and administrative expenses fell 20.8%. Annualising H1 cost levels suggests a path toward breakeven if revenue stabilises.
-
Optionality. Mainland standards keep expanding (342 to 396), and PuraPharm retains a licensed, certified plant. A reopened private-hospital channel, a clinical-asset success, or a strategic or state-linked investor (Providence's principal has a Shenzhen SASAC background) could re-rate a stock trading near book value.
Bear case
-
Liquidity could force a dilutive or distressed outcome. Cash of HK$12.2M covers 4% of current borrowings. Loans are already in default or covenant breach, and the auditor flags material uncertainty. Any lender withdrawal from RMB lines would be severe.
-
Revenue erosion continues. Group revenue fell for a fifth straight period (H1 2026 −7.3%). The growth initiatives are faltering: e-commerce −20.4%, Shenzhen clinics halved, US −22.6%, Japan −43.3%. Meanwhile HK CCMG segment profit fell 61% in H1 2026.
-
Governance and dilution overhang. A connected-party IP purchase was paid in shares, and the licensor's beneficial ownership is ambiguous. The chair/CEO roles are combined. Further equity raises are being sought at a share price about 44% below the October 2025 placement price.
Catalysts and monitorables (next 12 months)
-
Outcome of lender negotiations: default cure, term deferrals, covenant resets
-
Any new investor or asset disposal announcement (properties; Guizhou or Nanning assets)
-
FY2026 results (expected March 2026+1, i.e. ~March 2027), including whether the going-concern paragraph persists
-
H2 2026 HK CCMG volume and pricing; trend in inter-segment transfer pricing
-
Mainland national-standard count and any private-hospital or GBA traction
-
Use of Providence proceeds: clinical trial initiation in Hong Kong, Canadian NHP filing
-
Convertible bond conversion behaviour (conversion at HK$0.49 versus a HK$0.24 share price)
-
Clarification of BAGI Research ownership and related-party flows
-
Board stability following the 2025–2026 INED turnover
Analyst verdict
PuraPharm is a quality franchise trapped inside a fragile capital structure. Its Hong Kong CCMG business is a genuine niche leader. It claims more than 80% share, holds an unusually strong set of international quality certifications, and has delivered a 24–36% segment margin over five years. Together with the captive Nanning plant, it generated about HK$67M of segment profit in FY2025. On that measure the core business is clearly viable.
The group as a whole is not. The Mainland hospital business that once supplied more than half of revenue has gone to zero since national standards took effect. Restructuring the plantation and Mainland assets destroyed about HK$270M of book equity between FY2021 and FY2023. What remains is a roughly HK$320M revenue company carrying about HK$314M of mostly short-term RMB debt and only HK$12M of cash, with some loans in default.
Management has executed credibly on costs: S&D is down 76% and headcount 35%. It has also recapitalised modestly through the 2025 share issues and the 2026 convertible bond. But the working-capital release that funded deleveraging is exhausted, H1 2026 operating cash flow was negative, and each growth initiative is currently shrinking.
The equity is therefore a binary instrument. The upside case requires lenders to keep rolling facilities while a new strategic investor or asset sale materially de-risks the balance sheet. Under those conditions, a business trading at about 1x book and about 12x EBITDA could re-rate meaningfully. The downside case is a further heavily dilutive raise, or creditor-led restructuring, at prices well below the October 2025 placement level.
With no sell-side coverage, thin liquidity, combined chair and CEO roles, and an ambiguous related-party IP transaction, the governance discount is warranted. Verdict: speculative, special-situation profile. The core monitorable is lender behaviour, not product demand.
It is not investment advice.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Age (AR2025) | Tenure | Background and education | Source |
|---|---|---|---|---|---|
Chan Yu Ling, Abraham | Founder, Chairman, CEO, Executive Director; Nomination Committee chair | 65 | Founder 1998 | 30+ years in Chinese medicine; leads R&D. Vice chairman, Chinese Medicine Granule Professional Committee, China Association of TCM. B.A.Sc., University of Toronto; Chartered Engineer (UK); P.Eng. (Ontario). Spouse of Ms. Man. | AR2025 |
Man Yee Wai, Viola | Executive Director (corporate and brand strategy) | 60 | Since 1998 | Formerly Nestlé China (Key Account / Group Product Manager) and Coca-Cola China (Consumer Marketing Manager). Chairman of TWGHs (2012/13). Bronze Bauhinia Star (2013). B.Sc. (Western Ontario); MBA (Windsor). | AR2025 |
Dr. Tsoi Kam Biu, Alvin | Executive Director; ESG Committee chair | 69 | Director 2011–May 2021; re-appointed 30 Jun 2025 | 40+ years in sales management and Chinese medicine. Listed CMP. Doctorate in Dental Medicine (De Ocampo Memorial College); Bachelor in Chinese Medicine. | AR2025 |
Leung Stephen Kwok Keung | Non-executive Director | 69 | Appointment date not stated in reviewed filings (on the board by Feb 2025) | Pfizer 1983–2022, including Country Manager Hong Kong from 1997. B.Pharm (Liverpool John Moores); M.Bus (UMIST). Registered pharmacist (HK, UK). | AR2025 |
Dong Zimeng | Non-executive Director | 40 | Since 30 Oct 2025 | Managing partner of Providence Capital Group (SFC Type 9). Former president of Shenzhen Capital International (Shenzhen SASAC-owned). M.Sc./B.Eng. (Warwick). Ultimate owner of subscriber Providence Discovery Fund. | AR2025; FY25 Ann. |
Dr. Hung Ting On, John | INED; Audit Committee chair | 64 | Since 29 Aug 2025 | Former senior partner of Deloitte Asia Pacific; vice chairman of Deloitte China. Hon. LLD and MBA (Warwick); fellow and past president, ICAEW China Chapter. | AR2025 |
Dr. Leung Lim Kin, Simon | INED; Remuneration Committee chair | 71 | Appointment date not stated in reviewed filings | Former CEO of Microsoft Greater China and president of Motorola Asia-Pacific. Vice chairman of NetDragon (0777.HK); chairman of Mynd.ai. DBA (PolyU). | AR2025 |
Lee Stephen | INED; Audit Committee member | — | Appointed in 2026 (exact date not disclosed in IR26) | Biography not available in reviewed documents | IR26 |
Prof. Ng Wang Wai, Charles | INED; Audit Committee member | — | Appointed in 2026 (exact date not disclosed in IR26) | Biography not available in reviewed documents | IR26 |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Role | Detail |
|---|---|---|
Shi Gang | VP Greater China, age 70 | Joined Oct 2004; PRC regulatory and government liaison (AR2025) |
Chan Charmayne | Company Secretary | ACG, HKACG (AR2025) |
Anthony Siu | Senior Financial Advisor; ESG Committee member | Appointed 9 Apr 2025 (AR2025) |
Kwong Kar Fai | Head of Supply Chain | ESG Committee member (AR2025) |
Zhou Jian | Nanning Production Director | ESG Committee member (AR2025) |
Cheung Kwun Kiu | Financial Controller | Per Yahoo Finance profile (aggregator) |
CFO | No CFO disclosed | — |
“—” = not publicly disclosed.
Governance Overview
| Feature | Status |
|---|---|
Board size | 9 (3 ED, 2 NED, 4 INED) after 2026 changes |
Independence | 4 of 9 INEDs (44%) |
Chair / CEO | Combined in the founder. This is a disclosed deviation from CG Code C.2.1 (FY25 Ann.; IR26). |
Committees | Audit (4 INEDs; chair Hung), Remuneration (chair Leung Simon), Nomination (chair Chan), ESG (management-level; chair Tsoi) |
Family ties | CEO and ED Man are spouses |
Gender diversity | 1 female director of 9 (11%) after the 2026 changes (analyst-computed) |
Major Shareholders
| Holder | Shares | % of 535.9M |
|---|---|---|
Fullgold Development Ltd (100% Chan) | 81,929,000 | 15.29 |
PuraPharm Corporation Ltd (BVI; via Joint Partners Investments, owned 50/50 by Chan and Man) | 76,349,750 | 14.25 |
Mr. Chan (direct) | 40,108,267 | 7.48 |
Gold Sparkle Ltd (100% Chan) | 19,576,080 | 3.65 |
Ms. Man (direct) | 8,226,050 | 1.54 |
Chan and associates subtotal | 226,189,147 | 42.21 |
The Licensor (Patent Licence Agreement; identified in IR26 as BAGI Research Limited) | 93,488,372 | 17.45 |
Providence Discovery Fund (Dong Zimeng) | 46,512,000 | 8.68 |
Dr. Tsoi (ED) | 2,527,000 | 0.47 |
Dr. Leung Simon (INED) | 18,000 | 0.003 |
Share award trust | 844,335 | 0.16 |
Other public | 166,318,793 | 31.04 |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Revenue (latest) | Positioning vs PuraPharm |
|---|---|---|---|
China Traditional Chinese Medicine Holdings (0570.HK; Sinopharm subsidiary; brands Tianjiang and Yifang) | Mainland CCMG; also HK presence | FY2025 group revenue RMB14.74bn (−10.7%); CCMG RMB6.10bn (−12.5%); net loss RMB0.46bn (HKEX FY2025 results) | Mainland CCMG leader at roughly 160x PuraPharm's scale; also squeezed by centralised procurement |
China Resources Sanjiu (000999.SZ) | Mainland CCMG, OTC | — | State-backed scale player in CCMG and OTC |
Beijing Tong Ren Tang group (incl. 1666.HK / 3613.HK) | HK and Mainland TCM retail, clinics, OTC | — | Heritage brand with HK retail and clinic footprint; competes in clinics and health products |
Eu Yan Sang (private) | HK TCM retail, clinics, health products | — | Strong HK consumer brand; direct clinic and OTC rival |
Wai Yuen Tong Medicine (0897.HK) | HK proprietary Chinese medicine, health products | — | Local HK consumer TCM brand |
Sun Ten Pharmaceutical (Taiwan) | Granule exports to HK and overseas | — | Taiwanese granule competitor in HK private-practitioner and export markets |
Kaiser Pharmaceutical (Taiwan) | Granules (HK, overseas) | — | Same |
KPC Herbs, Mayway, Evergreen Herbs (US) | US herbal formulas vs KAN | — | US practitioner-market rivals to KAN Herb |
Japanese health-food makers (various) | Japan health foods vs SODX | — | Fragmented market |
University-affiliated and NGO TCM clinics in HK | Clinics | — | Low-cost competition for consultations |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | PuraPharm (1498.HK) | China TCM (0570.HK) |
|---|---|---|
Revenue | HK$336.1M | RMB14,744.8M |
Revenue growth YoY (%) | -12.0 | -10.7 |
Gross margin (%) | 53.6 | 48.1 |
CCMG segment revenue growth (%) | HK -7.4; China -100 | -12.5 |
Net result | Loss HK$35.2M | Loss RMB0.46bn |
R&D / revenue (%) | 4.1 | 3.5 (RMB511.5M per SA/S&P) |
Recent Developments
The window is extended back to January 2025 to capture the capital restructuring.



